CSKN Medical Limited
(previously Esho Medical Limited)
Unaudited Financial Statements
For the year ended 31 March 2024
Pages for Filing with Registrar
Company Registration No. 12406526 (England and Wales)
CSKN Medical Limited
(previously Esho Medical Limited)
Contents
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 9
CSKN Medical Limited
(previously Esho Medical Limited)
Balance Sheet
As at 31 March 2024
Page 1
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
549,893
333,391
Current assets
Stock
50,883
10,000
Debtors
4
697,400
626,882
Cash at bank and in hand
209,879
591,896
958,162
1,228,778
Creditors: amounts falling due within one year
5
(748,464)
(669,411)
Net current assets
209,698
559,367
Total assets less current liabilities
759,591
892,758
Creditors: amounts falling due after more than one year
6
(122,548)
(78,901)
Net assets
637,043
813,857
Capital and reserves
Called up share capital
7
1
1
Profit and loss reserves
637,042
813,856
Total equity
637,043
813,857

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

CSKN Medical Limited
(previously Esho Medical Limited)
Balance Sheet (Continued)
As at 31 March 2024
Page 2
The financial statements were approved and signed by the director and authorised for issue on 16 February 2026
Dr O O Esho
Director
Company Registration No. 12406526
CSKN Medical Limited
(previously Esho Medical Limited)
Notes to the Financial Statements
For the year ended 31 March 2024
Page 3
1
Accounting policies
Company information

CSKN Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is 6th Floor, Charlotte Building, 17 Gresse Street, London, United Kingdom, W1T 1QL. On 15 July 2025, the company changed its name from Esho Medical Limited.

1.1
Accounting convention

These financial statements have been prepared in accordance with section 1A of FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
Straight line method over 10 years
Plant and equipment
25% reducing balance basis
Fixtures and fittings
25% reducing balance basis
Computers
25% reducing balance basis
Motor vehicles
25% reducing balance basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

CSKN Medical Limited
(previously Esho Medical Limited)
Notes to the Financial Statements (Continued)
For the year ended 31 March 2024
1
Accounting policies
(Continued)
Page 4

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.5
Stock

Stock are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stock to their present location and condition.

Stock held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stock over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

CSKN Medical Limited
(previously Esho Medical Limited)
Notes to the Financial Statements (Continued)
For the year ended 31 March 2024
1
Accounting policies
(Continued)
Page 5
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

CSKN Medical Limited
(previously Esho Medical Limited)
Notes to the Financial Statements (Continued)
For the year ended 31 March 2024
1
Accounting policies
(Continued)
Page 6
1.12
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
10
10
CSKN Medical Limited
(previously Esho Medical Limited)
Notes to the Financial Statements (Continued)
For the year ended 31 March 2024
Page 7
3
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 April 2023
194,991
334,960
529,951
Additions
74,395
300,317
374,712
Disposals
-
0
(77,866)
(77,866)
At 31 March 2024
269,386
557,411
826,797
Depreciation and impairment
At 1 April 2023
58,497
138,063
196,560
Depreciation charged in the year
21,976
93,419
115,395
Eliminated in respect of disposals
-
0
(35,051)
(35,051)
At 31 March 2024
80,473
196,431
276,904
Carrying amount
At 31 March 2024
188,913
360,980
549,893
At 31 March 2023
136,494
196,897
333,391
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Corporation tax recoverable
8,180
-
0
Amounts owed by group undertakings
660,880
626,882
Other debtors
24,237
-
Prepayments and accrued income
4,103
-
0
697,400
626,882
CSKN Medical Limited
(previously Esho Medical Limited)
Notes to the Financial Statements (Continued)
For the year ended 31 March 2024
Page 8
5
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
9,996
9,669
Trade creditors
193,185
26,387
Corporation tax
110,437
166,112
Other taxation and social security
138,955
357,148
Other creditors
273,089
88,595
Accruals and deferred income
22,802
21,500
748,464
669,411
6
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
11,682
22,036
Other creditors
110,866
56,865
122,548
78,901
7
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
1
1
1
1
8
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
53,227
-
0
9
Related party transactions
CSKN Medical Limited
(previously Esho Medical Limited)
Notes to the Financial Statements (Continued)
For the year ended 31 March 2024
9
Related party transactions
(Continued)
Page 9

Included in other debtors a balance of £453,380 (2023: £362,037) due from CSKN Pharma Limited, a company under common control.

It also includes £199,500 (2023 : £264,845) due from CSKN Franchising Limited, a company under common control.

All are repayable on demand and interest free.

Included in other debtors is an amount of £24,237 (2023 : £5,558 owed to) owed by Dr O O Esho, director of the company. Interest of £1,283 has been charged on this loan.

10
Parent company

CSKN Holdings Limited is the parent undertaking of the company, the registered office of which is 2nd Floor Gadd House, Arcadia Avenue, London, England, N3 2JU.

Dr O O is the ultimate controlling party of the company by virtue of his directorship in the company and shareholding in CSKN Holdings Limited.

2024-03-31 2023-04-01 false false false CCH Software CCH Accounts Production 2025.300 No description of principal activity Dr O O Esho 12406526 2023-04-01 2024-03-31 12406526 2024-03-31 12406526 2023-03-31 12406526 core:LandBuildings 2024-03-31 12406526 core:OtherPropertyPlantEquipment 2024-03-31 12406526 core:LandBuildings 2023-03-31 12406526 core:OtherPropertyPlantEquipment 2023-03-31 12406526 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 12406526 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 12406526 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 12406526 core:Non-currentFinancialInstruments core:AfterOneYear 2023-03-31 12406526 core:ShareCapital 2024-03-31 12406526 core:ShareCapital 2023-03-31 12406526 core:RetainedEarningsAccumulatedLosses 2024-03-31 12406526 core:RetainedEarningsAccumulatedLosses 2023-03-31 12406526 core:ShareCapitalOrdinaryShareClass1 2024-03-31 12406526 core:ShareCapitalOrdinaryShareClass1 2023-03-31 12406526 bus:Director1 2023-04-01 2024-03-31 12406526 core:LandBuildings core:LongLeaseholdAssets 2023-04-01 2024-03-31 12406526 core:PlantMachinery 2023-04-01 2024-03-31 12406526 core:FurnitureFittings 2023-04-01 2024-03-31 12406526 core:ComputerEquipment 2023-04-01 2024-03-31 12406526 core:MotorVehicles 2023-04-01 2024-03-31 12406526 2022-04-01 2023-03-31 12406526 core:LandBuildings 2023-03-31 12406526 core:OtherPropertyPlantEquipment 2023-03-31 12406526 2023-03-31 12406526 core:LandBuildings 2023-04-01 2024-03-31 12406526 core:OtherPropertyPlantEquipment 2023-04-01 2024-03-31 12406526 core:CurrentFinancialInstruments 2024-03-31 12406526 core:CurrentFinancialInstruments 2023-03-31 12406526 core:Non-currentFinancialInstruments 2024-03-31 12406526 core:Non-currentFinancialInstruments 2023-03-31 12406526 bus:OrdinaryShareClass1 2023-04-01 2024-03-31 12406526 bus:OrdinaryShareClass1 2024-03-31 12406526 bus:OrdinaryShareClass1 2023-03-31 12406526 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 12406526 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 12406526 bus:FRS102 2023-04-01 2024-03-31 12406526 bus:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 12406526 bus:FullAccounts 2023-04-01 2024-03-31 xbrli:pure xbrli:shares iso4217:GBP